Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T22977
|
||||
Former ID |
TTDR00265
|
||||
Target Name |
Superoxide dismutase [Cu-Zn]
|
||||
Gene Name |
SOD1
|
||||
Synonyms |
Superoxide dismutase; SOD1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Dermatitis [ICD9: 692.9; ICD10: L20-L30] | ||||
Motor neurone disease [ICD9: 335.2; ICD10: G12.2] | |||||
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
|
||||
BioChemical Class |
Oxidoreductases acting on superoxide as acceptor
|
||||
UniProt ID | |||||
EC Number |
EC 1.15.1.1
|
||||
Sequence |
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ |
||||
Structure |
1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD; 1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO;2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD
|
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
BioCyc Pathway | Reactive oxygen species degradation | ||||
KEGG Pathway | Peroxisome | ||||
Amyotrophic lateral sclerosis (ALS) | |||||
Huntington' | |||||
s disease | |||||
Prion diseases | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
FOXA1 transcription factor network | |||||
PathWhiz Pathway | Degradation of Superoxides | ||||
Reactome | Platelet degranulation | ||||
Detoxification of Reactive Oxygen Species | |||||
WikiPathways | Oxidative Stress | ||||
Copper homeostasis | |||||
Detoxification of Reactive Oxygen Species | |||||
Nifedipine Activity | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Dopamine metabolism | |||||
AGE/RAGE pathway | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 521926 | ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health. | ||||
Ref 522202 | ClinicalTrials.gov (NCT00592579) A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma. U.S. National Institutes of Health. | ||||
Ref 525361 | Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. doi: 10.1038/ijir.2008.30. Epub 2008 Jul 24. | ||||
Ref 528378 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | ||||
Ref 535595 | Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. Epub 2002 Oct 29. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.